Breast Cancer Clinical Trials & Research at Providence Medical Group

In the U.S., breast cancer is the second most common cancer in women after skin cancer. It can occur in both men and women. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Breast cancer can also begin in the cells of the lobules and in other tissues in the breast. Invasive breast cancer is breast cancer that has spread from where it began in the ducts or lobules to surrounding tissue.

Providence Medical Group is currently enrolling patients for the following breast cancer clinical trials:

A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Pembrolizumab (BriaCell Rollover) - ON HOLD

Treatment agent: SV-BR-1-GM + Pembrolizumab
PI: Jarrod Holmes, MD
Study Coordinator: Kim
Resources and Links: clinicaltrials.gov NCT No: NCT03328026

An Open-label Multicenter Study Evaluating the Safety of Lasofoxifene in Combination with Abemaciclib for the treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and have an ESR1 MutationAn

Treatment agent: Lasofoxifene and abemaciclib
PI: Ian Anderson, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809 ext. 1182
Resources and Links: https://clinicaltrials.gov/ct2/show/NCT04432454